Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 21-valent conjugate vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Capvaxive (V116) is a 21-valent pneumococcal conjugate vaccine developed by Merck (MSD) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Approved by the FDA in June 2024, it is specifically designed to cover the serotypes responsible for approximately 84% of invasive pneumococcal disease in adults aged 65 and older. The vaccine includes eight unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B) that are not covered by other currently licensed pneumococcal vaccines. Capvaxive consists of purified capsular polysaccharides from 21 *Streptococcus pneumoniae* serotypes, each individually conjugated to a CRM197 carrier protein. This conjugation enhances the immune response by converting T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby inducing immunological memory and higher antibody titers. The vaccine is administered as a single intramuscular injection and does not contain an adjuvant.
- Brand names
- Capvaxive
- Other names
- PCV21PCV-21PCV 21Pneumococcal 21-valent Conjugate VaccinePneumococcal21-valent Conjugate VaccinePneumococcal-21-valent Conjugate Vaccine
02
Targets
10A CPS (Streptococcus pneumoniae serotype 10A capsular polysaccharide)11A CPS (Streptococcus pneumoniae serotype 11A capsular polysaccharide)12F CPS (Streptococcus pneumoniae serotype 12F capsular polysaccharide)15B CPS (Streptococcus pneumoniae serotype 15B capsular polysaccharide)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS Type 20 (Streptococcus pneumoniae serotype 20 capsular polysaccharide)CPS 22F (Streptococcus pneumoniae serotype 22F capsular polysaccharide)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)33F CPS (Streptococcus pneumoniae serotype 33F capsular polysaccharide)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)CPS 9N (Streptococcus pneumoniae serotype 9N capsular polysaccharide)
Beyond the preview
Go deeper on pneumococcal 21-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 21-valent conjugate vaccine.